AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$NBIX

Boyer David W. sold $130K of NBIX

Boyer David W. (Chief Corp. Affairs Officer) sold 826 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $157.45 ($0.13M total) on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Boyer David W.
Published Sep 15, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NBIX
Neutral
high confidence
Mentioned
$NBIX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NBIXNeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to move the stock.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data releases could make any insider activity more scrutinized.

Relevance 3/10Novelty 4/10Timing: 2026-09-14 (post‑market filing)

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$NBIXNeutralHigh confidence
Context

Chief Corp. Affairs Officer sold 826 shares for $130,050 via a 10b5-1 plan on 2026-09-14.

Expected impact

No significant move expected.

Evidence & confidence

The transaction size is modest relative to float and disclosed via a pre‑arranged plan.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market only.

Global

Low

Counterpoint

What could challenge this read

If NBIX shares are thinly traded, even a modest sale could signal insider concern.

Key entities

  • Officer
    Boyer David W.

    Chief Corp. Affairs Officer of Neurocrine Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NBIX insider trading history →

Related articles

$NBIXHighAI 8/10

NBIX Stock Jumps As Earnings Smash Estimates And Pipeline Expands

Neurocrine Biosciences Inc. (NBIX) stock rose 14.3% after strong Q3 earnings, with revenue of $1.12B (up from $794.9M YoY) and adjusted EPS of $3.29 (up from $2.17). The company also reported positive clinical data and expanded its pipeline, including a new Phase 2 trial for Alzheimer's treatment. Management raised FY26 revenue guidance to $2.9B–$2.925B, below consensus of $3.9B.

timothysykes.com
$NBIXHighAI 9/10

Why is Neurocrine Biosciences stock surging today?

Neurocrine Biosciences (NBIX) stock rose 15.1% after reporting Q3 adjusted earnings of $3.29 per share, beating estimates by 72%, and revenue of $1.12 billion, up 41% YoY. The company surpassed $1 billion in net product sales for the first time, driven by its top products. Analysts raised price targets, with Baird setting a $225 target. Management increased 2026 INGREZZA sales guidance to $2.9-$2.925 billion.

investing.com
$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com